Biosimilarity: The FDA Perspective

Biosimilarity: The FDA Perspective

by Sarfaraz K. Niazi

NOOK Book(eBook)

$50.99 $57.95 Save 12% Current price is $50.99, Original price is $57.95. You Save 12%.
View All Available Formats & Editions

Available on Compatible NOOK Devices and the free NOOK Apps.
WANT A NOOK?  Explore Now

Overview

Summary:

The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity.  An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.

Features:

First comprehensive analysis based on new guidelines and approval packages of several biosimilars

Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.

Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines

Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies

Allow creation of a fast-to-market pathway to develop biosimilars

Product Details

ISBN-13: 9781315351377
Publisher: CRC Press
Publication date: 10/03/2018
Sold by: Barnes & Noble
Format: NOOK Book
Pages: 398
File size: 4 MB

About the Author

Sarfaraz K. Niazi Ph.D,  is Adjunct Professor at the faculty of University of Houston as well Chairman and President of Therapeutic Proteins Inc.

Table of Contents

Current Status of Biosimilar Biological Products. The FDA Position. Biosimilarity Tetrahedron. Analytical and Functionality Similarity. Non-clinical Assessment. Clinical Pharmacology Assessment. Clinical Studies. Interchangeability Status. Comprehensive Presentation

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews